SWEDISH ORPHAN BIOVITRUM A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  1.5% 1.7% 1.6% 1.9% 1.9%  
Credit score (0-100)  78 73 73 69 68  
Credit rating  A A A A A  
Credit limit (kDKK)  103.2 28.5 50.8 6.5 8.1  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  31,624 39,028 32,623 23,486 22,183  
EBITDA  4,283 5,112 3,912 3,653 4,242  
EBIT  4,256 5,103 3,896 3,644 4,234  
Pre-tax profit (PTP)  4,697.9 5,533.5 4,318.3 4,231.3 5,510.3  
Net earnings  3,491.9 4,278.4 3,349.7 3,173.3 4,187.7  
Pre-tax profit without non-rec. items  4,698 5,533 4,318 4,231 5,510  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  17.6 49.5 33.5 24.1 16.1  
Shareholders equity total  16,667 20,946 24,295 27,469 31,656  
Interest-bearing liabilities  1,291 0.0 735 0.0 315  
Balance sheet total (assets)  30,767 36,717 33,718 32,145 36,485  

Net Debt  1,290 -1.0 735 -2,450 -3,089  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  31,624 39,028 32,623 23,486 22,183  
Gross profit growth  -10.3% 23.4% -16.4% -28.0% -5.5%  
Employees  0 0 0 0 10  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  30,767 36,717 33,718 32,145 36,485  
Balance sheet change%  8.1% 19.3% -8.2% -4.7% 13.5%  
Added value  4,282.9 5,111.8 3,912.3 3,659.7 4,242.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -54 24 -32 -19 -16  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  13.5% 13.1% 11.9% 15.5% 19.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  16.0% 16.5% 12.4% 13.0% 16.1%  
ROI %  29.5% 28.6% 19.0% 16.3% 18.6%  
ROE %  23.4% 22.7% 14.8% 12.3% 14.2%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  54.2% 57.0% 72.1% 85.5% 86.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  30.1% -0.0% 18.8% -67.1% -72.8%  
Gearing %  7.7% 0.0% 3.0% 0.0% 1.0%  
Net interest  0 0 0 0 0  
Financing costs %  2.9% 3.9% 12.0% 11.7% 17.8%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  2.3 2.8 3.6 6.8 7.5  
Current Ratio  2.3 2.8 3.6 6.8 7.5  
Cash and cash equivalent  1.0 1.0 0.0 2,450.1 3,404.1  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  17,207.2 23,410.4 24,096.2 27,274.6 31,461.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 424  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 424  
EBIT / employee  0 0 0 0 423  
Net earnings / employee  0 0 0 0 419